Orgenesis

OverviewSuggest Edit

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.
TypePrivate
Founded2008
Websiteorgenesis.com

Latest Updates

Employees (est.) (Nov 2018)231(+125%)
Revenue (FY, 2019)$33.3 M(+79%)
Share Price (Sept 2020)$4.8 (-4%)
Cybersecurity ratingAMore

Key People/Management at Orgenesis

Guy Yachin

Guy Yachin

Director
Neil Reithinger

Neil Reithinger

Chief Financial Officer, Secretary, and Treasurer
David Sidransky

David Sidransky

Director
Yaron Adler

Yaron Adler

Director
Evan Fishman

Evan Fishman

Chief Financial Officer
Ashish Nanda

Ashish Nanda

Director
Show more

Orgenesis Office Locations

Orgenesis has an office in Germantown
Germantown, US
Goldrenrod Building, 20271 Goldenrod Ln
Show all (1)

Orgenesis Financials and Metrics

Summary Metrics

Founding Date

2008
Show all financial metrics

Orgenesis Revenue

Orgenesis's revenue was reported to be $33.26 m in FY, 2019
USD

Revenue (Q2, 2020)

1.7m

Gross profit (Q2, 2020)

1.5m

Gross profit margin (Q2, 2020), %

86.1%

Net income (Q2, 2020)

20.4m

EBIT (Q2, 2020)

26.8m

Cash (30-Jun-2020)

97.5m
Annual
USDFY, 2011FY, 2012FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.0m6.4m10.1m18.7m33.3m

Revenue growth, %

115%

Cost of goods sold

3.9m7.7m6.8m10.8m18.2m

Gross profit

(906.0k)(1.3m)3.3m7.8m15.0m
Quarterly
USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

820.4k936.2k1.5k1.1k1.8k1.9m2.3m2.6m2.6m4.0m6.2m7.3m7.8m9.1m1.9m1.7m

Cost of goods sold

973.0k1.3m1.5k2.0k1.8k1.9m1.1m1.9m1.6m2.2m3.4m4.3m4.9m6.4m170.0k243.0k

Gross profit

(152.6k)(389.5k)40.0(832.0)20.0(53.0k)1.2m695.0k992.0k1.8m2.8m3.0m2.8m2.8m1.7m1.5m

Gross profit Margin, %

(19%)(42%)3%(73%)1%(3%)51%27%38%45%46%41%36%30%91%86%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.3k347.050.8k1.3m4.2m891.0k3.5m16.5m12.0m

Accounts Receivable

1.2m1.2m1.3m4.2m8.5m

Prepaid Expenses

1.1k28.2k36.9k105.0k1.1m841.0k913.0k1.2m

Inventories

301.0k400.0k725.0k1.7m2.0m
Quarterly
USDQ3, 2011

Financial Leverage

-0.2 x
Show all financial metrics

Orgenesis Acquisitions / Subsidiaries

Company NameDateDeal Size
Tamir Biotechnology IncJuly 07, 2020$21 m

Orgenesis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Orgenesis Online and Social Media Presence

Embed Graph

Orgenesis News and Updates

Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts

GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), has entered into a Services Agreement with Therapeutics, Inc., a premier U.S. Clinical R…

Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

Provides update on COVID-19 therapeutic programs

Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of Tumor Infiltrating Lymphocytes

GERMANTOWN, Md., June 01, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs) while lowering costs, today announces th…

Orgenesis Announces Agreement to Acquire Assets of Tamir Biotechnology, Inc. Including Broad Spectrum Antiviral Platform

Strategy to combine ranpirnase antiviral platform with Bioxome™ technology Strategy to combine ranpirnase antiviral platform with Bioxome™ technology

Orgenesis CEO Vered Caplan Provides Letter to Shareholders

GERMANTOWN, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs), provides the followin…
Show more

Orgenesis Frequently Asked Questions

  • When was Orgenesis founded?

    Orgenesis was founded in 2008.

  • Who are Orgenesis key executives?

    Orgenesis's key executives are Guy Yachin, Neil Reithinger and David Sidransky.

  • How many employees does Orgenesis have?

    Orgenesis has 231 employees.

  • What is Orgenesis revenue?

    Latest Orgenesis annual revenue is $33.3 m.

  • What is Orgenesis revenue per employee?

    Latest Orgenesis revenue per employee is $144 k.

  • Who are Orgenesis competitors?

    Competitors of Orgenesis include Virta Health, Lophius Biosciences and Mesoblast.

  • Where are Orgenesis offices?

    Orgenesis has an office in Germantown.

  • How many offices does Orgenesis have?

    Orgenesis has 1 office.